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Abstract
Background: To review the demographic data of a series of adenoid cystic carcinoma (ACC) of
the tongue, as well as to analyze c-kit expression, histopathologic patterns, prognostic factors,
evolution, recurrences and/or persistence and survival.
Methods: Retrospective study from 1986 to 2006, which reviews a database of 68 patients with
diagnosis of head and neck ACC.
Results: We found eight cases of ACC of the tongue (11.7% of all head and neck ACCs). There
were 7 female (87.5%) and 1 male (12.5%) patients, with an average age of 51 years (range 33 to
67 years). Seven patients were surgically treated, three of which required adjuvant treatment. Only
one female patient did not accept treatment. Average follow-up time was 5.3 years. Metastases
developed in 37% of cases during the follow-up period. Histopathologically, the cribriform pattern
predominated (6/8 cases). All cases presented perineural invasion, and one patient also presented
vascular invasion. c-kit positivity was observed in all cases. Global survival in the seven treated cases
was 51% and 34% at 5 and 10 years, respectively, while the disease-free period was of 64% at 3
years and 42% at 10 years.
Conclusion: ACC of the tongue is a rare neoplasm, in which early diagnosis is important because
these are slowly-growing tumors that produce diffuse invasion. As the role of c-kit could not be
assesed in this series, surgery continues to be the cornerstone of treatment and radiotherapy is
indicated when surgical margins are compromised. Metastatic disease is still hard to handle because
of the lack of adequate therapies for these tumors. Hence, survival has not changed in the last years.
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Adenoid cystic carcinoma (ACC) is a malignant neoplasm
that originates in both the minor and major salivary
glands, characterized by slow growth, diffuse invasion
and potential to produce distant metastases, mainly to the
lungs and bones [1]. It is an infrequent lesion, as it repre-
sents approximately 1% to 2% of all malignant neo-
plasms of the head and neck, and up to 10% to 15% of all
malignant salivary gland neoplasms [2]. The most com-
mon intraoral site for minor salivary gland tumors is the
hard palate, followed by the base of the tongue [3] where
up to 96% of all tumors are malignant, and ACC repre-
sents 30% of them [4,5]. On the other hand, one of the
least frequent sites of presentation for ACC is the mobile
tongue, as several authors have reported an incidence of
only approximately 3% of the cases [6]. Likewise, it has
been reported that in this location, 75% are in stages T3
and T4 at the time of diagnosis [7]. Histopathologically,
ACC may present in three different patterns: solid, tubu-
lar, and cribriform; perineural invasion is common and
has been reported in almost half of the cases. Necrosis and
vascular invasion are present at a lower rate [6].
The cornerstone of treatment is surgery, while radiother-
apy has been considered for advanced T stages and as
adjuvant in the presence of positive microscopic margins
[8]. Some authors suggest that advanced and non-resecta-
ble tumors may be treated only with radiotherapy [9].
It has recently been found that c-kit (CD-117), a tyrosine-
kinase receptor involved in growth and development of
normal tissues and in some neoplasms [10] expresses in
ACC; previous studies have found its expression in 78% of
45 cases[11] and in 78.5% of 14 cases[10], which led
some to consider the use of tyrosine kinase inhibitors
such as imatinib mesylate as an adjuvant and/or therapeu-
tic tool to manage distant metastases[12].
The objectives of our study were to review the demo-
graphic data of ACC of the tongue diagnosed at our insti-
tution, to assess c-kit expression in these tumors and to
describe the histopathological patterns, prognostic factors
(such as perineural and vascular invasion), as well as evo-
lution, recurrences and/or persistence and survival of
patients.
Methods
This is a retrospective study that comprises the period of
1986 to 2006, which reviews a database of 68 patients
with ACC of the head and neck region treated at the Insti-
tuto Nacional de Cancerologia of Mexico. We included in
this study only those patients with ACC of the tongue.
Their clinical stage at the time of admission was deter-
mined according to the AJCC 2002[13]. We reviewed the
clinical files and performed a new histopathological study
of each patient to assess stage and microscopic pattern,
perineural and vascular invasion and c-kit (CD 117)
expression, except in one patient for which only the slides
but not the paraffin blocks were available. Demographic
and clinical information were collected from the clinical
files, including the following data: age, gender, time of
evolution prior to diagnosis, TNM classification, initial
and adjuvant treatment, presence of perineural invasion,
recurrences, presence of metastases, general overall sur-
vival and disease-free survival at 5 and 10 years according
to Kaplan and Meier.
Results
We found eight cases of ACC of the tongue (6 at the base
and 2 in the mobile tongue), which represent 11.8% of all
ACC of the head and neck area assessed at our institution
during the period of study. There were seven female
(87.5%) and one male (12.5%) patients with an average
age of 51 years (range 33–67 years). All cases were staged,
except for one recurring patient. The salient clinical fea-
tures are shown in Table 1.
Seven patients were treated with surgery, three of which
required adjuvant treatment: two with radiotherapy (aver-
age of 59 Gy per patient), one due to perineural invasion
and the other because of presenting regional lymph node
metastases. The latter patient received concomitant
chemo-radiotherapy due to positive surgical margins
aside from the regional metastases. Only one female
patient of the original eight did not accept treatment. The
average follow-up time was 5.3 years. During follow-up,
37% of the patients presented pulmonary metastases (one
accompanied by bone metastases) (Table 2). Histopatho-
logically, the cribriform pattern predominated (6/8
cases). All patients presented perineural invasion, and one
case presented also vascular invasion. Immunohisto-
chemistry with c-kit was positive in all the reviewed cases
(Table 3).
Overall survival in the seven treated cases was 51% and
34% at 5 and 10 years, respectively. Disease-free survival
was 64% at 3 years and 42% at 5 and 10 years.
Discussion
Neoplasms of accesory salivary gland origin occur less
commonly than those arising from major salivary glands.
Several studies indicate that malignant lesions account for
a greater percentage of accesory salivary gland tumors as
compared to major salivary glands. Tongue is a relatively
uncommon site for salivary gland neoplasms [14].
ACC is an extremely unpredictable neoplasm regarding its
evolution and behavior as it grows slowly, regional metas-
tases are infrequently seen, but it tend to produce late dis-
tant metastases; however this condition does not lead to aPage 2 of 6
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report ACC series of the head and neck [4,8,15,16], we
also found that ACC located in the tongue occurs more
frequently in female patients.
Previous series of ACC of the head and neck region have
shown that the frequency in wich the tongue has been the
site of origin ranged from 3.4% to 17.1% [3,4,11,15,17].
We found a similar figure in our series of 68 cases, where
tongue location represented 11.8%, which is also similar
to Khafif et al. [3] results. Also similar was the fact that in
that study mobile tongue was the primary location in
2.9% and the base of the tongue in 8.8%, whereas we
found a 3% and 8.8% respectively for such locations.
With respect to head and neck cases of ACC, Silverman et
al. [8] found that 46.3% were in clinical stages I and II and
53.7% in stages III and IV; in contrast, the report of 34
patients by Khafif et al. [3] showed 64% in early stages (I
and II), and 35% in advanced stages (III and IV). In our
study we had 87.5% of cases in advanced clinical stage,
which is higher than what has been reported in the litera-
ture. These diferences may be explained by the fact that
when located in the tongue, the clinical course of this neo-
Table 1: Clinical features and treatment of ACC.
Case Gender Age Location T N M CS Surgery performed
1 F 38 Base of tongue (left) 4 0 0 IVA Left hemiglossectomy
2 F 48 Base of tongue (left) - - - No* Total glossectomy + total laryngectomy + floor of mouth resection + 
reconstruction with pectoral flap
3 F 64 Base of tongue (left) 2 1 0 III Hemiglossectomy + left base of tongue excision + supraomohyoid left neck 
dissection + reconstruction with pectoral flap.
4 F 40 Base of tongue (left) 4 0 X IVA Total glossectomy + floor of mouth resection + reconstruction with pectoral 
flap.
5 F 33 Mobile tongue 4 2c 1 IV Total glossectomy + modified right neck dissection + supraomohyoid left neck 
dissection + reconstruction with microvascular flap from the anterior 
abdominal rectus abdomen.
6 F 57 Mobile tongue 3 1 0 III Marginal resection with CO2 laser + antero-lateral dissection of the left neck
7 M 67 Base of tongue (right) 3 0 0 III Primary tumour resection + radical right neck dissection.
8 F 63 Base of tongue 3 0 0 III Did not accept treatment
*not classified for being a recurrence. CS: clinical stage
Table 2: Follow-up of treated patients.
Case Metastatic lymph nodes Distant metastases Follow-up time
(months)
Current Status
1 No No 207 AWoD
2 No Bilateral pulmonary 84 DWD
3 Yes, lymph node conglomerate No 84 LWoD
4 No Bilateral pulmonary 60 DWD
5 2/8 base of tongue Pulmonary and bone 2.5 LWD
6 1/38 No 6 AWoD
7 2/39 No 0 DWoD
LWoD: Lost without disease, LWD: lost with disease, DWD: dead with disease, AWoD: alive without disease, DWoD: dead without disease.Page 3 of 6
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tumoral growth, which hinders an early diagnosis; conse-
quently the time elapsed from the first clinical manifesta-
tion through diagnosis is long, as it has been estimated
from 6 months to 8 years[16], while in our series the
mean was 15 months. In this sense, most tumors located
at the base of the tongue are in advanced stages at the time
of diagnosis, as shown by Goepfert et al[7], who found
that 75% of their ACC cases were in stages T3 and T4,
which is similar to our findings. On the other hand,
although tumors located in the mobile tongue produce
more functional alterations and hence, should be diag-
nosed at an earlier stage, this was not seen in our series,
where tumors ranged in size from 2 to 15 cm (Figures 1,
2, 3). The reason of this is not clear, but it may be related
to the lack of pain in several cases, as well as socio-cultural
and economic background of our patients.
Surgery is the cornerstone of treatment, and its extension
depends primarily on the size of the tumor. It may be per-
formed in the form of partial glossectomy, hemiglossec-
tomy, total glossectomy with/without preservation of the
larynx, or total glossectomy with/without reconstruction
if the case merits it. For cases requiring reconstruction, this
can be accomplished with a flap, either pedunculated
(from the pectoral) or free microvascular flap (wide dorsal
muscle, abdominal rectus, antebranchial) [18,19]. The
relevance and extent of surgery relies on the early diagno-
sis and, consequently, on the T stage. As can be observed
in our series dealing with advanced stages, total glossec-
tomy and larynx preservation had to be performed in four
cases with pectoral flap reconstruction in three of them,
and in one case with a free flap from the abdominal rec-
tus; the latter, in our experience, is the best option as it
provides adequate volume [20].
The use of adjuvant radiotherapy is still controversial; on
one side, there are authors that recommend it for an
advanced T stage with positive margins [8], whereas other
authors have obtained an increase in local control rate at
5 or 10 years, advocating for this therapeutic option in all
patients [9]. We used radiotherapy in three cases. Based in
our experience with other head and neck tumors [21], we
believe that concomitant chemo-radiotherapy represents
an alternative for patients with advanced disease or to pre-
serve organs, but its use has not been explored as primary
treatment or as post-surgical adjuvancy. Besides, as it is
well known, it is relatively inefficacious in the treatment
Table 3: Anatomopathologic assessment of ACC of tongue.
Case Stage Pattern Perineural invasion Vascular invasion Margins c-kit expression
1 II Cribriform yes No - +
2 II Cribriform yes No - +
3 II Cribriform yes No - +
4 I Tubular yes No - +
5 III Solid yes Yes - +
6 II Cribriform yes No + +
7 II Cribriform yes No - +
8 II Cribriform yes No * +
* Patient did not accept surgery
57 year old female with a lateral mobile tongue ACCFigure 1
57 year old female with a lateral mobile tongue ACC.Page 4 of 6
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plasm. In this respect, several agents have been proven
with low rates of response, such as cisplatin, 5-fluorour-
acil, adriamycin and cytoxan, either alone or in combina-
tion [22].
Relevance of c-kit expression lies in its possible role to
direct treatment of non-resectable or metastatic disease,
although the use of imatinib mesylate as tyrosine kinase
inhibitor is still controversial. In this respect, there are
some contradictory results in the literature, as for exam-
ple, favorable results have been presented by Alcedo et al.
[12] in 2 cases of unresectable ACC treated with imatinib
mesylate, one for recurrent disease and the other for a
locally advanced tumor; however there are other authors
who have observed progression of the disease during
treatment with imatinib mesylate[23]. The seven patients
in whom c-kit expression was assessed were all positive;
however, c-kit activation was not assessed, which would
be an important step to decide to treat or not with tyrosine
kinase inhibitors, because mutations in 11 c-kit and 9 c-
kit exons condition an 83.5% and 47.8% response,
respectively, in contrast to patients with non detectable c-
kit mutation, who do not present an objective response
[24]. As the results at present are derived from small series
or from isolated case-reports with more questions than
answers on the benefit of tyrosine kinase inhibitors and
due to their high cost, we have not been able to pursue
treatment with these drugs in our patients.
In our study, one case presented distant metastases at the
time of diagnosis and two during the follow-up (2 pulmo-
nary and 1 pulmonary and bone metastases). These
patients have had a follow-up of 7 years, 5 years, and 2.5
months, respectively, and have died due to causes related
to the neoplasm. One female patient presented a regional
lymph node conglomerate, which was treated with neck
dissection and adjuvant radiotherapy; after 7 years of fol-
low-up she is currently without data of tumoral activity.
These findings suggest that even in spite of advanced
staged or metastatic disease it is possible to offer radical
surgical treatment, as these patients may follow a slow
course of the disease with longer survival as compared to
other types of tumors with similar advanced disease.
The most common histological subtype in our study was
the cribriform, just like in other series. Its relevance lies in
that the solid subtype depicts the worst prognosis, with a
survival of 34% at 10 years, in contrast to the 76% of the
cribriform and the 100% of the tubular subtypes [25]. The
histological subtypes of lower-grade malignancy (tubular
and cribriform) have a better prognosis than those of high
malignancy (solid) as the latter are associated with recur-
rences, early distant metastases, and a higher mortality
rate [25], as occurred in our female patient (No 5), the
only one with solid pattern, who presented the largest
tumor (15 × 11 cm) in the mobile tongue, with a growth
evolution of only 10 months. The presence of perineural
invasion was found in 100% of our cases. Previous studies
have shown that this implies a worse prognosis, decreas-
ing survival to 76% against 100% of those not presenting
it [25]. According to the AFIP (Armed Forces Institute of
Pathology) the tongue is the site of occurrence of malig-
nanat neoplasms in 58.2% in males and 56.6% in
females, and ACC predominates in the 5th and 6th decade
of life. From a registry of all ACC (600 cases) tongue rep-
resented a 17.1% with 30 cases [17].
33 year old female with a massive infiltration of the tongue due to ACCFigure 2
33 year old female with a massive infiltration of the 
tongue due to ACC.
An anterolateral tumor of the mobile tongue shown by the arrowFigure 3
An anterolateral tumor of the mobile tongue shown 
by the arrow.Page 5 of 6
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in other series of ACC of the head and neck, as that of da
Cruz Perez et al. [5] from Brazil, who showed 56.5% and
32.5% at 5 and 10 years respectively; this contrasts with
the disease-free survival, which in our cases was 42% at 10
years, and only 29% in the previously reported Brazilian
study[5], which could be related to more radical treatment
modalities employed in our cases.
Conclusion
ACC of the tongue is a very infrequent neoplasm; early
diagnosis and proper treatment are important factors
from a functional point of view, since these are slowly-
growing tumors that may produce diffuse invasion. As the
role of c-kit could not be assesed in this series, surgery
continues to be the cornerstone of treatment and radio-
therapy is indicated in the presence of compromised sur-
gical margins. Metastatic disease is still hard to handle
because of the lack of adequate therapies for these tumors
and therefore survival has not changed in the last years.
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